Eli Lilly shares fell as much as 4.1% in premarket trading following a report that competitor Novo Nordisk intends to reduce U.S. prices for its diabetes and weight-loss drugs Ozempic and Wegovy by up to 50%.

According to the report, the monthly price for both medications will be set at $675 starting January 1, 2027.